|
JPH0515775Y2
(https=)
|
1987-07-13 |
1993-04-26 |
|
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
ATE459616T1
(de)
|
1998-08-11 |
2010-03-15 |
Novartis Ag |
Isochinoline derivate mit angiogenesis-hemmender wirkung
|
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
ATE273695T1
(de)
|
2000-06-28 |
2004-09-15 |
Smithkline Beecham Plc |
Nassvermahlung
|
|
IL160915A0
(en)
|
2001-09-19 |
2004-08-31 |
Aventis Pharma Sa |
Indolizines inhibiting kinase proteins
|
|
ES2269793T3
(es)
|
2001-10-30 |
2007-04-01 |
Novartis Ag |
Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
|
|
TW200406374A
(en)
|
2002-05-29 |
2004-05-01 |
Novartis Ag |
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
CL2003002353A1
(es)
|
2002-11-15 |
2005-02-04 |
Vertex Pharma |
Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
|
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
WO2005105814A1
(en)
|
2004-04-28 |
2005-11-10 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
RU2007123675A
(ru)
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
WO2009064835A1
(en)
|
2007-11-16 |
2009-05-22 |
Incyte Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
CA3121743A1
(en)
|
2009-01-15 |
2010-07-22 |
Incyte Holdings Corporation |
Processes for preparing jak inhibitors and related intermediate compounds
|
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
JP5775070B2
(ja)
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
KR101921850B1
(ko)
|
2009-10-09 |
2018-11-23 |
인사이트 홀딩스 코포레이션 |
3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
|
|
EP2536729A1
(en)
|
2010-02-18 |
2012-12-26 |
Incyte Corporation |
Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
|
|
PT3354652T
(pt)
|
2010-03-10 |
2020-07-20 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
|
KR20130094710A
(ko)
|
2010-04-14 |
2013-08-26 |
어레이 바이오파마 인크. |
Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
|
|
RS54824B1
(sr)
|
2010-05-21 |
2016-10-31 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
|
EP2678686B1
(en)
|
2011-02-24 |
2017-10-11 |
Massachusetts Institute of Technology |
ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
WO2013041042A1
(en)
|
2011-09-22 |
2013-03-28 |
Merck Sharp & Dohme Corp. |
Pyrazole carboxamides as janus kinase inhibitors
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
CN104918945B
(zh)
|
2012-11-01 |
2018-01-05 |
因赛特公司 |
作为jak抑制剂的三环稠合噻吩衍生物
|
|
CN113384546A
(zh)
|
2012-11-15 |
2021-09-14 |
因赛特公司 |
鲁索利替尼的缓释剂型
|
|
WO2014138168A1
(en)
|
2013-03-06 |
2014-09-12 |
Incyte Corporation |
Processes and intermediates for making a jak inhibitor
|
|
TWI651300B
(zh)
|
2013-05-17 |
2019-02-21 |
健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
US9371282B2
(en)
|
2013-05-17 |
2016-06-21 |
Centrexion Therapeutics Corporation |
Somatostatin receptor subtype 4 (SSTR4) agonists
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
CN105209470B
(zh)
|
2013-05-17 |
2018-02-06 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶
|
|
SMT201900223T1
(it)
|
2013-05-17 |
2019-07-11 |
Incyte Corp |
Sale di bipirazolo come inibitore di jak
|
|
SG10201801069QA
(en)
|
2013-08-07 |
2018-03-28 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
CN105555313A
(zh)
|
2013-08-20 |
2016-05-04 |
因赛特公司 |
在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
|
|
EP3060234A1
(en)
*
|
2013-10-24 |
2016-08-31 |
AbbVie Inc. |
Jak1 selective inhibitor and uses thereof
|
|
JP6576941B2
(ja)
|
2014-02-28 |
2019-09-18 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
骨髄異形成症候群の治療のためのｊａｋ１阻害剤
|
|
CN106687462A
(zh)
|
2014-04-30 |
2017-05-17 |
因赛特公司 |
Jak1抑制剂的制备方法以及其新形式
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
HRP20192009T1
(hr)
|
2014-12-16 |
2020-02-07 |
Novartis Ag |
Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
|
|
TW201705961A
(zh)
*
|
2015-06-11 |
2017-02-16 |
阿爾米雷爾有限公司 |
作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
|
|
EP4012415A3
(en)
|
2015-12-04 |
2022-12-07 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
KR20190021200A
(ko)
|
2016-03-22 |
2019-03-05 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
독성을 예방 또는 경감시키기 위한 조기 개재 방법
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
MY200629A
(en)
*
|
2017-08-01 |
2024-01-06 |
Theravance Biopharma R&D Ip Llc |
Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
|
IL311485B1
(en)
*
|
2018-02-16 |
2026-01-01 |
Incyte Corp |
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
|
|
MD3773593T2
(ro)
|
2018-03-30 |
2024-10-31 |
Incyte Corp |
Tratament hidradenitei supurative utilizând inhibitori ai JAK
|
|
WO2019191679A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
|
CA3097025A1
(en)
|
2018-04-13 |
2019-10-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
US11633399B2
(en)
|
2018-12-25 |
2023-04-25 |
Sol-Gel Technologies Ltd. |
Treatment of skin disorders with compositions comprising an EGFR inhibitor
|
|
TW202106681A
(zh)
*
|
2019-04-24 |
2021-02-16 |
美商施萬生物製藥研發Ｉｐ有限責任公司 |
用於治療皮膚疾病之嘧啶jak抑制劑
|
|
WO2021076124A1
(en)
*
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
|
|
US20210346279A1
(en)
|
2020-05-07 |
2021-11-11 |
Sol-Gel Technologies Ltd. |
Compositions comprising tapinarof for the treatment of pruritis
|
|
FI4157831T3
(fi)
|
2020-06-02 |
2024-12-02 |
Incyte Corp |
Menetelmiä jak1-estäjän valmistamiseksi
|